Recently, Pfaender et al. (2020) reported that the lymphocyte antigen 6 complex, locus E (LY6E) protein potently restricts cellular infection by multiple coronaviruses, including SARS-CoV-2. Using GENEVESTIGATOR® across multiple compendia and platforms, we screened thousands of experimental conditions to study the gene expression regulation of LY6E. Here are some of the most significant effects we found:
|IFNb-1a (Avonex)||HS-01577 / Neutrophils isolated from peripheral blood samples of patients with multiple sclerosis 24 hours after the first treatment with IFNb-1A (Avonex). Control: patients before treatment.||137x upregulation|
|Influenza||HS-03257 / Plasmacytoid dendritic cells isolated from the blood of healthy donors were treated 24h with influenza A/PR/8/34 (H1N1) virus. Control: Plasmacytoid dendritic cells isolated from healthy donors.||20x upregulation|
|Lupus||LY6E is strongly upregulated in several SLE case-control studies||10-40x upregulation|
|IFM-a2b||HS-00230 / Immature dendritic cells treated with 1000 u/ml of IFN-a2b. Control: without treatment||7x upregulation|
|Brefeldin A||HS-01936 / LY6E is downregulated in response to Brefeldin A treatment.||6x downregulation|
|Sepsis||HS-01577 / LY6E is strongly downregulated in neutrophils isolated from peripheral blood samples of patients with sepsis as compared to healthy subjects.||200x downregulation|
Table: Conditions causing an up- or downregulation of the LY6E gene, as identified using the Perturbations tool in GENEVESTIGATOR®.